ライフサイエンスコーパス: indocyanine

1 aration of the first restrained heptamethine indocyanine.

2 d structure of pentamethine and heptamethine indocyanines.

3 n angiography (FFA), OCT angiography (OCTA), indocyanine angiography (ICGA), and fundus autofluoresce

4 luster headache (n = 5) using fluorescein or indocyanine angiography.

5 y (OCT), en-face OCT, OCTA, fluorescence and indocyanine angiography.

6 Heptamethine indocyanines are invaluable probes for near-infrared (NI

7 All patients received intravenous indocyanine green (75 mg) between 16 and 24 hours before

8 Subjects received second window indocyanine green (ICG) (2.5-5 mg/kg) 24 hours prior to

9 frared (NIR) fluoresence dental imaging with indocyanine green (ICG) agent that has rarely been appli

10 ode tracer consisting of the fluorescent dye indocyanine green (ICG) and (99m)Tc-nanocolloid with the

11 Indocyanine green (ICG) and epirubicin (EPI) could co-se

12 n-based nano-formulations capable of loading indocyanine green (ICG) and therapeutic genes were prepa

13 in infrared reflectance (IR) photographs and indocyanine green (ICG) angiograms.

14 orescence (FAF), and fluorescein angiography/indocyanine green (ICG) angiography findings, of patient

15 Indocyanine green (ICG) angiography has been successfull

16 Indocyanine green (ICG) aqueous angiography established

17 glycated chitosan (GC) as immunoadjuvant and indocyanine green (ICG) as laser-absorbing dye have show

18 infrared (NIR) range, clinical potential of indocyanine green (ICG) as PT is limited by its short ha

19 Liver function was assessed by clearance of indocyanine green (ICG) at 4, 20 and 28 hours.

20 ood flow and function were determined by the indocyanine green (ICG) clearance test.

21 We report indocyanine green (ICG) conjugated with a 2100 Da PEG mo

22 The near-infrared dye indocyanine green (ICG) could serve as a basis for such

23 targeted liposomes loaded with J-aggregated indocyanine green (ICG) dye (i.e., PAtrace) that we synt

24 otic shock technique was used to encapsulate indocyanine green (ICG) dye in erythrocyte ghost cells a

25 /J mice was induced by combined injection of indocyanine green (ICG) dye into the anterior chamber an

26 velocimetry (EMV) is a novel technique where indocyanine green (ICG) dye is sequestered in erythrocyt

27 espectively tracked iron oxide particles and indocyanine green (ICG) encapsulated in the NPs as trace

28 ogenase (LDH) activity, bile production, and indocyanine green (ICG) extraction.

29 trate the predictive ability of quantitative indocyanine green (ICG) fluorescence angiography for the

30 Indocyanine green (ICG) fluorescence imaging could be us

31 OCT and indocyanine green (ICG) fluorescence were used to evalua

32 secondary lymphedema in the extremities, but indocyanine green (ICG) fluorescent lymphography, the re

33 tomography (DOT) after the administration of indocyanine green (ICG) for contrast enhancement.

34 Hyperfluorescent cells labeled with indocyanine green (ICG) have been observed in retinal an

35 I) using an intraoperative injection of free indocyanine green (ICG) in the detection of peritoneal m

36 sed signal strength by as much as 36.3%, and indocyanine green (ICG) increased signal magnitudes by a

37 ceived 0.5 mg per kilogram of body weight of indocyanine green (ICG) intravenously 24 hours prior to

38 Indocyanine green (ICG) is a fluorescent dye taken up an

39 on and lower autofluorescence; however, only indocyanine green (ICG) is clinically approved.

40 trapping ability of CM, the photosensitizer indocyanine green (ICG) is successfully loaded and retai

41 Indocyanine green (ICG) is the most commonly used FDA-ap

42 Indocyanine green (ICG) is the only near-infrared (NIR)

43 Indocyanine green (ICG) is the only NIR dye with regulat

44 normal female volunteers underwent bilateral indocyanine green (ICG) lymphography and lymphoscintigra

45 ymphatic drainage was measured at day 60 via indocyanine green (ICG) lymphography, after which animal

46 -enhanced Raman scattering (SERS) studies on indocyanine green (ICG) on colloidal silver and gold and

47 The data indicated that (1) formulated indocyanine green (ICG) readily penetrated hyperkeratoti

48 study was to evaluate the performance of the indocyanine green (ICG) retention test as a noninvasive

49 Both indocyanine green (ICG) solution and TA suspension, at 5

50 Indocyanine green (ICG) stain was used in 22 eyes (25.2%

51 (GQDs), directing site-selective assembly of indocyanine green (ICG) that turns on photoinduced elect

52 Indocyanine green (ICG) was administered intravenously 1

53 to evaluations, hamsters were injected with indocyanine green (ICG), a fluorescent dye that binds to

54 as been uniquely accomplished with NIR using indocyanine green (ICG), a nonspecific dye that has comp

55 tiated to RPE (hiPSC-RPE) cells labeled with indocyanine green (ICG), an FDA approved dye, were trans

56 Here we report that indocyanine green (ICG), an infrared fluorescent dye wit

57 nd Drug Administration-approved dyes such as indocyanine green (ICG), but has a caveat of suboptimal

58 lowly releasing a pressurized cuff occluding indocyanine green (ICG), demonstrated an increase in ves

59 tein (GFP), tricarbocyanine 5.5 (Cy5.5), and indocyanine green (ICG), filters were selected to allow

60 yaluronic acid (HA)-dopamine (HD), including indocyanine green (ICG), were developed for local therap

61 e well-known and widely used fluorescent dye indocyanine green (ICG), which has FDA approval, exhibit

62 traprostatic tracer administration of either indocyanine green (ICG)-(99m)Tc-nanocolloid (hybrid-trac

63 ntraprostatic injection of the hybrid tracer indocyanine green (ICG)-(99m)Tc-nanocolloid enables both

64 ng that the hybrid sentinel node (SN) tracer indocyanine green (ICG)-(99m)Tc-nanocolloid generates te

65 al use of SNB, either with the hybrid tracer indocyanine green (ICG)-(99m)Tc-nanocolloid or with free

66 The fluorophore outperformed indocyanine green (ICG)-a clinically approved NIR-I dye-

67 rs, and 24 hours after systemic injection of indocyanine green (ICG).

68 ear infrared fluorescence (NIR) images using Indocyanine green (ICG).

69 leted mice erythrocyte-ghosts and doped with Indocyanine Green (ICG).

70 ugated with a near-infrared fluorescent dye [indocyanine green (ICG)] targets low extracellular pH, a

71 Fluorescein (FA) and indocyanine green (ICGA) angiography (Heidelberg Spectra

72 t the pH low-insertion peptide conjugated to indocyanine green (pHLIP ICG), currently in clinical tri

73 Indocyanine green and BPD angiography were performed in

74 liposomes loaded with an optimized ratio of indocyanine green and doxorubicin, denoted as LID, effic

75 ting (electrophysiology, fundus photography, indocyanine green and fluorescein angiography, and magne

76 mography (OCT), fundus autofluorescence, and indocyanine green and fluorescein angiography, was avail

77 nusoidal endothelial cells were evaluated by indocyanine green and hyaluronic acid uptake.

78 Indocyanine green and OCT angiography revealed numerous

79 eceived a standardised cervical injection of indocyanine green and sentinel-lymph-node mapping follow

80 fundus photographs, fluorescein angiograms, indocyanine green angiograms, and optical coherence tomo

81 he success rate of laser treatment guided by indocyanine green angiographic findings can vary conside

82 in an area of hypofluorescence on late-phase indocyanine green angiographic images.

83 ng color fundus photography, fluorescein and indocyanine green angiographies, spectral-domain optical

84 luding retinography, SD-OCT, fluorescein and indocyanine green angiography (FA & ICGA) and adaptive o

85 tients underwent fluorescein angiography and indocyanine green angiography (FA/ICGA), swept-source or

86 T, fundus fluorescein angiography (FFA), and indocyanine green angiography (ICG) by 2 independent obs

87 Indocyanine green angiography (ICG) was used to identify

88 s photography, fluorescein angiography (FA), indocyanine green angiography (ICG), optical coherence t

89 ce (FAF), OCT, fluorescein angiography (FA), indocyanine green angiography (ICGA) and OCT angiography

90 atients diagnosed with CSC who underwent UWF indocyanine green angiography (ICGA) and widefield OCT i

91 To investigate indocyanine green angiography (ICGA) findings in patient

92 Concurrent fluorescein angiography (FA) and indocyanine green angiography (ICGA) images were used to

93 nce (FAF), fluorescein angiography (FA), and indocyanine green angiography (ICGA) imaging to evaluate

94 Indocyanine green angiography (ICGA) showed central hypo

95 escence in the topography of the lesion, and indocyanine green angiography (ICGA) showed hypofluoresc

96 l choroidal vasculopathy was diagnosed using indocyanine green angiography (ICGA) with the scanning l

97 escence (FAF), fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical cohere

98 escence (FAF), fluorescein angiography (FA), indocyanine green angiography (ICGA), and SD-OCT were pe

99 hy (OCTA), fluorescein angiography (FA), and indocyanine green angiography (ICGA), and the images fro

100 imultaneous fluorescein angiography (FA) and indocyanine green angiography (ICGA), enhanced-depth ima

101 al vasculopathy (PCV) is best diagnosed with indocyanine green angiography (ICGA), ICGA is often unav

102 (CFP), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), optical coherence

103 eflectance, fundus autofluorescence imaging, indocyanine green angiography (ICGA), preferential hyper

104 obtained using fluorescein angiography (FA), indocyanine green angiography (ICGA), structural optical

105 ts except for choroidal hyperpermeability on indocyanine green angiography (ICGA).

106 hypofluorescence of the plaque on late-phase indocyanine green angiography (ICGA).

107 he entire fundus using ultra-widefield (UWF) indocyanine green angiography (ICGA).

108 d imaging, fluorescein angiography (FA), and indocyanine green angiography (ICGA).

109 our department, 167 cases were confirmed by indocyanine green angiography (ICGA).

110 icolor imaging, fluorescein angiography, and indocyanine green angiography (ICGA).

111 CT, OCT-A, fluorescein angiography (FA), and indocyanine green angiography (ICGA).

112 data on demographics, clinical features, and indocyanine green angiography (ICGA).

113 rate vitritis, and hypocyanescent lesions on indocyanine green angiography (ICGA).

114 tations of venous overload on ultrawidefield indocyanine green angiography (UWF ICGA) include asymmet

115 olypoidal lesion (PL) closure at week 12 per indocyanine green angiography .

116 Baseline fluorescein angiography and indocyanine green angiography also were performed.

117 Advances in imaging, particularly in indocyanine green angiography and optical coherence tomo

118 nd fundus imaging, including fluorescein and indocyanine green angiography and optical coherence tomo

119 patients with extrafoveal PCV, confirmed on indocyanine green angiography and treated with argon las

120 In dry macular degeneration, indocyanine green angiography appears to add clinically

121 In certain circumstances, indocyanine green angiography can be valuable in detecti

122 Indocyanine green angiography confirmed choroidal inflam

123 Infrared thermography and indocyanine green angiography confirmed the presence of

124 vidence of retinal vasculitis or papillitis, indocyanine green angiography evidence of active choroid

125 Indocyanine green angiography excluded Vogt-Koyanagi-Har

126 Indocyanine green angiography findings, particularly at

127 refraction, colour imaging, fluorescein and indocyanine green angiography findings, together with B-

128 Indocyanine green angiography has allowed us to look at

129 For the past year, indocyanine green angiography has been applied to evalua

130 sarcoidosis in intraocular inflammation, and indocyanine green angiography has clarified choroidal in

131 The relative safety of indocyanine green angiography has contributed to its con

132 developments in the clinical application of indocyanine green angiography have mainly concerned refi

133 ted color fundus photographs fluorescein and indocyanine green angiography images to determine the su

134 coherence tomography [OCT], fluorescein and indocyanine green angiography images) were analyzed.

135 ptical coherence tomography, fluorescein and indocyanine green angiography in a 66 years old man suff

136 t-naive patients diagnosed with PCV based on indocyanine green angiography in accordance with publish

137 rrelated with the polypoidal lesions seen on indocyanine green angiography in all PCV eyes.

138 erns of abnormal hyperfluorescence seen with indocyanine green angiography in eyes with both wet and

139 al coherence tomography, and fluorescein and indocyanine green angiography in patients suspected of h

140 udies demonstrating choroidal involvement by indocyanine green angiography in patients with HTLV-1-as

141 Indocyanine green angiography is improving our understan

142 defield fluorescein angiography results, and indocyanine green angiography results were collected.

143 Indocyanine green angiography revealed chroidal vascular

144 Indocyanine green angiography revealed dilated hyperperm

145 Indocyanine green angiography revealed the presence of c

146 Indocyanine green angiography revealed tortuous choroida

147 d 1970s, the introduction of fluorescein and indocyanine green angiography revolutionized our ability

148 was confirmed by fluorescein angiography and indocyanine green angiography testing.

149 Upon comparison with indocyanine green angiography videoangiography (ICG-VA)

150 Indocyanine green angiography was performed at baseline

151 nding hypofluorescence in 100% of cases when indocyanine green angiography was performed.

152 ence tomography angiography, fluorescein and indocyanine green angiography was performed.

153 nce tomography, fluorescein angiography, and indocyanine green angiography were graded.

154 us examination, fluorescein angiography, and indocyanine green angiography were included.

155 olor images, and fluorescein angiography and indocyanine green angiography were measured before and a

156 l diameter and thickness and fluorescein and indocyanine green angiography were no different in the 2

157 Fluorescein and indocyanine green angiography were performed in patients

158 FA), optical coherence tomography (OCT), and indocyanine green angiography were performed.

159 dalities such as magnetic resonance imaging, indocyanine green angiography, and digital image analysi

160 th fundus photography, OCT, OCT angiography, indocyanine green angiography, and fluorescein angiograp

161 depth imaging-OCT, fluorescein angiography, indocyanine green angiography, and fundus autofluorescen

162 as ultrasonography, fluorescein angiography, indocyanine green angiography, and magnetic resonance im

163 rements, fundus photography, fluorescein and indocyanine green angiography, and microperimetry.

164 uorescence imaging, fluorescein angiography, indocyanine green angiography, and optical coherence tom

165 sion, quality of life (QoL), fluorescein and indocyanine green angiography, and optical coherence tom

166 Ophthalmic CT, fluorescein angiography, indocyanine green angiography, and others are demonstrat

167 ser ophthalmoscopy, fluorescein angiography, indocyanine green angiography, and spectral-domain optic

168 ncluding fundus photography, fluorescein and indocyanine green angiography, fundus autofluorescence i

169 ddition, a subset of patients also underwent indocyanine green angiography, fundus fluorescein angiog

170 color photography, fluorescein angiography, indocyanine green angiography, near-infrared reflectance

171 prised fundus photography, autofluorescence, indocyanine green angiography, OCT, and OCT angiography.

172 s autofluorescence, fluorescein angiography, indocyanine green angiography, optical coherence tomogra

173 uorescence imaging, fluorescein angiography, indocyanine green angiography, or a combination thereof.

174 reaks and reduced fluorescence on late-phase indocyanine green angiography, prompted genetic testing

175 amination including fluorescein angiography, indocyanine green angiography, spectral-domain optical c

176 onography, OCT, fluorescein angiography, and indocyanine green angiography, was performed throughout

177 l imaging, including OCT and fluorescein and indocyanine green angiography, was reviewed for the pres

178 randomized at a 1:1 ratio to receive either indocyanine green angiography-guided half-dose PDT or or

179 ated with either half-dose PDT or HSML (both indocyanine green angiography-guided) and categorized in

180 omography, fluorescein angiography (FA), and indocyanine green angiography.

181 erence tomography (OCT), and fluorescein and indocyanine green angiography.

182 for fluorescence, including fluorescein and indocyanine green angiography.

183 ography, fundus fluorescein angiography, and indocyanine green angiography.

184 er with symptomatic macular PCV confirmed on indocyanine green angiography.

185 hy, and lack of choroidal vascular lesion on indocyanine green angiography.

186 birdshot spots" or characteristic imaging on indocyanine green angiography.

187 that corresponded to hypocyanescent spots on indocyanine green angiography.

188 th autofluorescence, SD-OCT, fluorescein and indocyanine green angiography.

189 fundus autofluorescence, and fluorescein and indocyanine green angiography.

190 tofluorescence, fluorescein angiography, and indocyanine green angiography.

191 good correlation with lesions identified on indocyanine green angiography.

192 lar evaluation by a simultaneous fluorescein/indocyanine green angiography.

193 t, and regression of polypoidal complexes on indocyanine green angiography.

194 Trypan Blue and Indocyanine Green appear to be most effective in stainin

195 ger-scale studies are essential to establish indocyanine green as a viable alternative rather than a

196 Intraoperative visualization of the SLN by indocyanine green before skin incision was successful in

197 tly faster lymphatic drainage as measured by indocyanine green clearance and increased lymphatic vess

198 llular function was determined by an in vivo indocyanine green clearance technique.

199 Indocyanine green clearance was measured in two animals

200 lationship between the increments in VO2 and indocyanine green clearance was observed (r2 = .21; p =

201 e maximal velocity and efficiency of in vivo indocyanine green clearance) was determined and hepatocy

202 l velocity and overall efficiency of in vivo indocyanine green clearance) were assessed at 24 hours a

203 ximum velocity and the overall efficiency of indocyanine green clearance) were determined at 4 hrs af

204 ximum velocity and the overall efficiency of indocyanine green clearance) were determined.

205 Indocyanine green clearance, as determined by a fiberopt

206 A noninvasive measurement of indocyanine green clearance, the plasma disappearance ra

207 velocity and transport efficiency of in vivo indocyanine green clearance.

208 , N-acetylcysteine elicits an improvement in indocyanine green clearance.

209 ut not VO2) and a nonsignificant increase in indocyanine green clearance.

210 The number of new indications for indocyanine green continues to increase, including innov

211 ulating blood volume were assessed using the indocyanine green dilution technique and a left ventricu

212 When indocyanine green dosages were 10 microg or higher, lymp

213 Indocyanine green dye (0.08 mg/ml in D5W) was injected s

214 EGF-Cy5.5, but not Cy5.5 or indocyanine green dye (ICG), bound to MDA-MB-468 cells.

215 ith 50- to 100-fold greater concentration of Indocyanine Green dye over background levels.

216 f the PKWS subject that transported injected indocyanine green dye to the inguinal lymph node and dra

217 Near-infrared reflectance measurements of indocyanine green dye uptake indicated that there were n

218 Indocyanine green dye was used as a nonspecific control

219 oxorubicin and photothermally active organic indocyanine green dye).

220 ining of the internal limiting membrane with indocyanine green dye, and variations in the length of p

221 Indocyanine green elimination constants (K(ICG)) were me

222 Based upon Indocyanine Green encapsulation within the nanoparticles

223 Mean rates of bile flow, biliary indocyanine green excretion, and bile acid flux were sig

224 Indocyanine green fluorescence imaging demonstrated comp

225 Indocyanine green fluorescence imaging is a surgical too

226 ependent or that refine the existing method: indocyanine green fluorescence, contrast-enhanced ultras

227 ls in the upper extremities, especially when indocyanine green fluorescent lymphography fails to depi

228 cutaneous melanoma on the trunk), the use of indocyanine green for SLN detection is severely limited

229 TATION: Sentinel lymph nodes identified with indocyanine green have a high degree of diagnostic accur

230 direct cannulation, perivascular flowprobe, indocyanine green imaging, and functional magnetic reson

231 systemic injection of the near-infrared dye indocyanine green in patients with various types of soli

232 l subcutaneous injections of 0.31-100 microg indocyanine green in the breast in this IRB-approved, HI

233 As such, simultaneous use of cyanine-5 and indocyanine green in the same patient proved to be feasi

234 h monkey was given a 0.75 mg/kg injection of indocyanine green in the saphenous vein.

235 Hepatic blood flow was determined by indocyanine green infusion.

236 l retrospective studies, the fluorescent dye indocyanine green is considered a possible alternative t

237 he tibial fracture sites using near-infrared indocyanine green lymphatic imaging (NIR-ICG) and discov

238 h dermal backflow of lymph was identified by indocyanine green lymphography, relative to those in the

239 FLT imaging with indocyanine green may improve the accuracy of cancer sur

240 Lymph imaging consistently failed with indocyanine green microdosages between 0.31 and 0.77 mic

241 is context, we propose evaluating the use of Indocyanine Green near-infrared (ICG-NIR) as a supplemen

242 ontrast-enhanced magnetic resonance imaging, indocyanine green near-infrared imaging, and intravital

243 In patients who received 10 microg of indocyanine green or more, a weak negative correlation b

244 tic function (transpulmonary thermodilution, indocyanine green plasma disappearance rate [ICG-PDR]) w

245 Immediately after administration, indocyanine green provided a significant increase in the

246 /-0.5 vs. 33.2+/-1.7 microg/min/g liver) and indocyanine green secretion (11.7+/-1.7 vs. 21.2+/-2.1 A

247 usion model, lactate dehydrogenase activity, indocyanine green secretion, and portal pressure values

248 antitative liver function tests, such as the indocyanine green test and galactose elimination capacit

249 , and an ex vivo spectrophotometric assay of indocyanine green uptake (1.87-fold increase in normaliz

250 ated similar hyaluronic acid uptake, whereas indocyanine green uptake was markedly impaired in the hy

251 perfusion) and in vivo (hyaluronic acid and indocyanine green uptake, arterial ketone body ratio, or

252 nanocolloid or (99m)Tc-nanocolloid with free indocyanine green used as tracers.

253 assessed clinically, photometrically, and by indocyanine green videoangiography.

254 At anesthesia induction, indocyanine green was injected intravenously.

255 that contained micromolar concentrations of indocyanine green with 1:0 and 100:1 target-to-backgroun

256 amine 800, Alexa Fluor 750, IRDye 800CW, and indocyanine green) and proteins (sfGFP, mCherry, mKate,

257 n wavelength) fluorescence (by using the dye indocyanine green) for aiding the fluorescence-guided su

258 nt for use in surgery, pHLIP ICG, where ICG (indocyanine green) is a surgical fluorescent dye used wi

259 of the feature sizes of a common NIR I dye (indocyanine green) showed a more rapid loss of feature c

260 , microvascular quadriceps blood flow index (indocyanine green), cardiac output (inert gas breathing)

261 ation of theranostic agents (doxorubicin and indocyanine green).

262 Indocyanine green, a near-infrared fluorescent dye that

263 ction frequency via near-infrared imaging of indocyanine green, and ankle bone volumes via micro-comp

264 uated the in vivo uptake of hyaluronic acid, indocyanine green, and radio-labeled sulphur colloid to

265 milar heptamethine fluorophores ZW800-1A and indocyanine green, and show that ZW800-1C undergoes a lo

266 shifted julolidine flavylium heterocycle and indocyanine green, distinct channels with well-separated

267 asers, combined with the clinically approved indocyanine green, enabled real-time, three-colour imagi

268 Using relatively high doses of indocyanine green, long-term enhanced fluorescence of ar

269 gent mixture composed of fluorescein sodium, indocyanine green, PCM102, and PCM107 and imaged with a

270 ctant Survanta(R) reduced the aPDT effect of indocyanine green, Photodithazine(R), bacteriochlorin-tr

271 Compared to clinically used indocyanine green, the QDs show superior brightness and

272 f the widely used label tdTomato and the dye indocyanine green, we show the importance of correct pho

273 yaluronic acid-coated gold nanoparticles and indocyanine green, which is widely used as a dye in vitr

274 nsitive amphiphilic polymer, conjugated with indocyanine green, which rapidly and irreversibly dissoc

275 The clinically applied hybrid tracer indocyanine green-(99m)Tc-nanocolloid enables combined r

276 ere considered candidates for SN biopsy with indocyanine green-(99m)Tc-nanocolloid or (99m)Tc-nanocol

277 e cancer during an SN biopsy procedure using indocyanine green-(99m)Tc-nanocolloid.

278 At the time of reperfusion, indocyanine green-based in vivo imaging showed that CD47

279 Administration-cleared devices designed for indocyanine green-based perfusion imaging to identify ca

280 hanced the tumor targeting of GSH-responsive indocyanine green-conjugated Au(25) nanoclusters coated

281 al nonimmobilized limb, confirmed by in vivo indocyanine green-enhanced NIR optical imaging (3.86-fol

282 of muscle damage was obtained using in vivo indocyanine green-enhanced NIR optical imaging, magnetic

283 Fusion of indocyanine green-enhanced optical imaging and radiograp

284 Indocyanine green-enhanced optical imaging is a clinical

285 Fusion of indocyanine green-enhanced optical imaging scans with ra

286 t encapsulate the near infrared chromophore, indocyanine green.

287 following intravenous injection of 10 mg/kg indocyanine green.

288 e hydrophilic analogs of clinically approved indocyanine green.

289 ved the poor performance of the FDA-approved indocyanine green.

290 ntroducing a near-infrared (NIR) dye such as indocyanine green.

291 stic signals compared with the commonly used indocyanine green.

292 Indocyanine-green angiography (ICG-A) may be considered

293 tofluorescence, fluorescein angiography, and indocyanine-green angiography (ICGA).

294 intravenous fluorescein angiography (IVFA), indocyanine-green angiography, and ophthalmic ultrasound

295 By the direct Fick, or the indocyanine-green or both, methods and by renal clearanc

296 PARTICIPANTS: The MIMIC (Minimally Invasive, Indocyanine-Guided Metastasectomy in Patients With Color

297 um benzoxazole (PyBox) salts as heptamethine indocyanine precursors.

298 Values of bile production, indocyanine secretion, and cellular damages were compara

299 ch as contact Dopplerography, intraoperative indocyanine videoangiography (ICG) video angiography, fl

300 Second, we developed cyclizing heptamethine indocyanines with the goal of improving cellular uptake